Everand Logo

Welcome to Everand!

  • STAT

    Alexion’s newly approved rare-disease drug notches another clinical trial win

    Alexion's newly approved rare-disease drug notches another clinical trial win — this time in patients with a rare type of kidney disease.
    by Adam Feuerstein Jan 28, 2019 1 minute
    Source: Kristoffer Tripplaar/SIPA/AP

    Alexion Pharmaceuticals (ALXN) said Monday that its newly approved drug Ultomiris achieved the primary goal of a late-stage clinical trial involving patients with a rare type of kidney disease.

    Based on the successful outcome of the clinical trial,

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
    A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
    The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
    New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

    Related